Araim Pharma enters strategic partnership with Vault Bioventures

Privately-held USA-based biotech firm Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies.

This new strategic collaboration is expected to leverage the expertise of Araim Pharmaceuticals in scientific discovery and research with Vault Bioventures' proven capability in clinical and regulatory development and commercialization in order to speed time-to-market, lower regulatory risk, and maximize commercial impact.

This collaboration is triggered by the transition of Araim Pharmaceuticals into the clinical stage of drug development following positive proof-of-concept studies in two distinct patient populations in two leading indications. The foundation for this collaboration is the innovative scientific platform of Araim, which has shown significant positive findings in a wide array of disease models, including in peripheral nerves (neuropathy), retinopathy, nephropathy, the central nervous system (neurodegeneration), cardiovascular injury, wound healing, and aging.